Astellas Maps ASCO 2026 Oncology Roster Across Disease Stages

The Astellas ASCO 2026 presentation roster outlines 10 abstracts, including two oral presentations, for the 2026 ASCO Annual Meeting in Chicago, May 29-June 2, 2026. The portfolio spans urothelial carcinoma, prostate cancer, a breast-cancer supportive-care study, and ASP2998 in solid tumors. The schedule names enfortumab vedotin, enzalutamide, fezolinetant, and ASP2998 across multiple programs. Overall, the lineup reaches across both advanced and earlier disease settings.

The bladder-cancer roster is led by T. Powles's oral EV-302 presentation. Abstract 4507 is scheduled for May 29 and compares enfortumab vedotin plus pembrolizumab with chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. Earlier-setting material includes P. O'Donnell's KEYNOTE-905 oral presentation, N. Adra's KEYNOTE-905 subgroup poster, and C. Hoimes's KEYNOTE-B15 poster in muscle-invasive bladder cancer. Those abstracts appear on May 30 and May 31 and extend the program from metastatic disease into perioperative and subgroup-focused bladder-cancer settings.

The prostate roster centers on enzalutamide analyses from EMBARK and ARCHES in nonmetastatic castration-sensitive disease with high-risk biochemical recurrence and metastatic castration-sensitive disease. On May 31, A. Armstrong and A. Stenzl are listed for ARCHES posters on treatment-duration predictors and efficacy and safety in patients with cardiometabolic comorbidities or related medications. S. Freedland is named on an EMBARK poster addressing testosterone recovery above 250 ng/dL after treatment suspension, and M. Schoen leads a veteran subgroup analysis. Astellas says these analyses are intended to add insight into treatment outcomes and clinical decision-making, and the entries extend established programs through analysis-driven follow-up.

C. Bouchard is listed for HIGHLIGHT 1, a trial in progress investigating fezolinetant for moderate to severe vasomotor symptoms in women with stage 0 to 3 hormone receptor-positive breast cancer receiving adjuvant endocrine therapy. The phase 3 study is randomized, placebo-controlled, and double-blind, and fezolinetant safety and efficacy are unestablished in that population. The same roster lists G. Sonpavde's poster on ASP2998, a TROP2-targeted immunostimulatory antibody-drug conjugate with dual payloads in a phase 1b/2 solid-tumor study. That poster is scheduled for May 30, while HIGHLIGHT 1 appears June 1, placing supportive-care work alongside an early-phase program later in the roster.